


Qnostics

Complete Quality Control Solutions for SARS-CoV-2 (COVID-19)





In response to the current Coronavirus outbreak, Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing has developed a range of products designed to support the validation, verification and performance monitoring of molecular assays used in the testing of SARS-CoV-2 (COVID-19). Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control. The use of third-party controls will allow laboratories to effectively monitor the performance of diagnostic methods.

Why Choose Qnostics?



Whole Pathogen Controls

Qnostics controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays. As whole pathogen controls they target the whole viral genome including CDC and WHO consensus sequences.



Full Process Control

Whole pathogen controls are the ideal material for full-process validation, monitoring the testing process from extraction to amplification and detection ensuring ultimate quality assurance in laboratories.



Highly Characterised

When the use of time and resources are critical like in COVID-19 testing, the use of highly characterised controls enables laboratories to meet their daily QC needs and accreditation requirements. Qnostics controls are quantified by digital PCR to ensure batch to batch reproducibility and are traceable to an internal reference preparation, to ensure metrological traceability of test results obtained by different diagnostic workflows.



True Third Party

An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.



Superior Manufacturing

Qnostics controls are manufactured under ISO 13485 guidelines to ensure quality and traceability.



Liquid for Ease-of-use

Conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.



Negative Control Available

Negative controls contain human cells/nucleic acids and therefore can be used as part of assay validation.

Complete QC Solutions

SARS-CoV-2 Q Controls

Whole pathogen controls designed to monitor assay performance on a run to run basis. As true third party controls, assay drift is detected, monitored and managed helping to ensure accurate and reliable results.

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – 5 day stability

Regulatory Status – CE, RUO

Ordering Information

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
SCV2QC	SARS-CoV-2 Q Control	5 x 0.5 ml
TMNQC	Negative Q Control	5 x 0.5 ml

SARS-CoV-2 Analytical Q Panel

Designed to span the analytical measuring range of an assay, allowing assessment of linearity, Limit of Detection (LOD) and Limit of Quantitation (LOQ).

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use

immediately.

Regulatory Status – CE, RUO

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
SCV2AQP	SARS-CoV-2 Analytical Q Panel	9 x 0.5 ml

SARS-CoV-2 Molecular Q Panel

Four individual levels including a negative are provided spanning the assays' clinical range. Molecular Q Panels may be used to support laboratory training and in the performance assessment and validation of molecular diagnostic assays.

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix - Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – CE, RUO

Ordering Information

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
SCV2MQP	SARS-CoV-2 Molecular Q Panel	4 x 0.5 ml

RESPIRATORY TARGET MULTIPLEX (RTX)

The Qnostics RTX 4-plex controls enables the requirements for testing strategies for the upcoming flu season to be met. These 4-plex controls cover the viral and bacterial pathogens responsible for an array of respiratory diseases in various patient cohorts, whilst discriminating cold and flu from COVID-19

RTX1 Q Control (RTX Plus)

Target Pathogen – Influenza A (H1N1), Influenza B (Victoria), RSV A, Coronavirus (SARS-CoV-2)

Target – Whole Pathogen

Matrix - Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – RUO

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
RTX1QC	RTX Q Control (RTX Plus)	5 x 0.6ml positive control

RTX2 Q Control

Target Pathogen – Parainfluenza 1, Adenovirus 1, Mycoplasma pneumoniae, Coronavirus (OC43)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – RUO

Ordering Information

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
RTX2QC	RTX2 Q Control	5 x 0.6ml positive control

RTX3 Q Control

Target Pathogen – Parainfluenza 2, Metapneumovirus (A2), Enterovirus (A16), Coronavirus (229E)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – RUO

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
RTX3QC	RTX3 Q Control	5 x 0.6ml positive control

RTX4 Q Control

Target Pathogen – Parainfluenza 3, Rhinovirus (16), Legionella pneumophila, Coronavirus (NL63)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – RUO

Ordering Information

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
RTX4QC	RTX4 Q Control	5 x 0.6ml positive control

RTX5 Q Control [for paediatric testing]

Target Pathogen – Parainfluenza 4, Adenovirus (14), RSV B, Enterovirus (D68)

Target – Whole Pathogen

Matrix - Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use

immediately.

Regulatory Status – RUO

CATALOGUE NUMBER	PRODUCT DESCRIPTION	PACK SIZE
RTX5QC	RTX5 Q Control	5 x 0.6ml positive control

Related Products

QCMD | MOLECULAR EQA SOLUTIONS FOR SARS-CoV-2

The SARS-CoV-2 programme is designed to assess the ability of laboratories to detect SARS-CoV-2 at clinically relevant levels, near the Limit of Detection (LOD) and to assess the specificity of the assay in the presence of other coronaviruses. Two flexible participation options are available including; a single challenge format comprising 10 samples or a two-challenge format comprising 5 samples per challenge.

Feature	Available Format(s)		
Catalogue Number	QAV204215_I	QAV204215_2	
Number of Challenges		2	
Number of Samples per Challenge	10	5	
Distribution / Testing Period	Q4	Q3 and Q4	

Specifications

Sample NA Target Source — Cultured and/or clinical material

Target Range — Covers the clinical range

Matrix – Transport Medium

Sample Volume — | ml

Analysis Type — Qualitative

Format – Liquid Frozen

QCMD 2020 Respiratory I Plus (RESPIplus)

The new RESPIplus EQA programme covers SARS-CoV-2 in addition to other respiratory pathogens including Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) and is ideal for laboratories using multiplex and/or cartridge based molecular systems. The programme is designed to assess the ability of molecular workflows in the detection and differentiation of SARS-CoV-2 in combination with other respiratory pathogen targets.

Feature Available Format(s)		
Catalogue Number	QAV204216_1	
Number of Challenges		
Number of Samples per Challenge	10	
Distribution / Testing Period	Q4	

Specifications

Sample NA Target Source — Cultured and/or clinical material

Target Range - Covers the clinical range

Matrix - Transport Medium

Sample Volume - | ml

Analysis Type — Qualitative

Format – Liquid Frozen

Qnostics Related Products

the below list is not exhaustive, please contact us for more information.



Transplant – Adenovirus, BK Virus, Cytomegalovirus, Epstein-Barr Virus (EBV), HSV-1, Varicella Zoster Virus (VZV)



Respiratory – Influenza A, Influenza B, Parainfluenza, RSV, Rhinovirus



Blood Borne - Hepatitis B (HBV), Hepatitis C (HCV), HIV



Exotic – West Nile, Zika Virus



Sexually Transmitted - Chlamydia trachomatis (CT), Neisseria gonorrhoea (NG)



Gastrointestinal – Norovirus



Meningitis & Encephalitis – Meningitis / Encephalitis (ME)



Fungal Infections - Candida, Aspergillus



Copyright © 2019 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative.